iBio to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Update on Tuesday, February 16, 2021
10 February 2021 - 8:30AM
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech
innovator and biologics contract manufacturing organization,
announced today that it will report its fiscal 2021 second quarter
financial results after market close on Tuesday, February 16, 2021.
iBio management will host a webcast and conference call at 4:30
p.m. Eastern Time to discuss the results and provide a corporate
update.
The live and archived webcast may be accessed on
the Company’s website at www.ibioinc.com under “News and Events” in
the Investors section. The live call can be accessed by dialing
(833) 672-0651 (domestic) or (929) 517-0227 (international) and
referencing conference code: 7891625.
About iBio, Inc.
iBio is a global leader in plant-based biologics
manufacturing. Its FastPharming® System
combines vertical farming, automated hydroponics, and glycan
engineering technologies to rapidly deliver high-quality monoclonal
antibodies, vaccines, bioinks and other proteins. iBio is
developing proprietary products on the
FastPharming Platform, which include
biopharmaceuticals for the treatment of fibrotic and infectious
diseases, amongst others. The Company’s subsidiary, iBio CDMO LLC,
provides FastPharming Contract
Development and Manufacturing Services along with the
Glycaneering™ Development
Services for the control and tailoring of N-glycosylation. For more
information, visit www.ibioinc.com.
Contact:
Stephen KilmeriBio, Inc.Investor Relations(646)
274-3580skilmer@ibioinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Apr 2024 to May 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From May 2023 to May 2024